Drugs that contain Exenatide Synthetic
1. List of Bydureon drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7223440
(Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Mar, 2022
(11 months ago) | |
| US6824822 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Oct, 2022
(3 months ago) | |
|
US6824822
(Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Apr, 2023
(2 months from now) | |
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 2 months from now) | |
| US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 2 months from now) | |
|
US9238076
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(1 year, 8 months from now) | |
|
US7563871
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(1 year, 8 months from now) | |
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(2 years from now) | |
|
US7612176
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(2 years from now) | |
|
US8461105
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(2 years from now) | |
|
US8431685
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(2 years from now) | |
|
US7456254
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(2 years from now) | |
|
US6515117
(Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(3 years from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(3 years from now) | |
| US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(3 years from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(3 years from now) | |
|
US8906851
(Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(4 years from now) | |
|
US9884092
(Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(4 years from now) | |
|
US8329648
(Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(4 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
| US8758292 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Nov, 2027
(4 years from now) | |
|
US8501698
(Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(4 years from now) | |
| US8216180 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jan, 2028
(4 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
| US8439864 | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Mar, 2028
(5 years from now) | |
| US9320853 | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Mar, 2028
(5 years from now) | |
|
US8758292
(Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
May, 2028
(5 years from now) | |
|
US8216180
(Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jul, 2028
(5 years from now) | |
|
US8361972
(Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(5 years from now) | |
|
US9320853
(Pediatric) | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Sep, 2028
(5 years from now) | |
|
US8439864
(Pediatric) | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Sep, 2028
(5 years from now) | |
| US8827963 | ASTRAZENECA AB | Administering device with holding mechanism |
Feb, 2029
(6 years from now) | |
| US8690837 | ASTRAZENECA AB | Mixing device for a two-chamber ampoule |
May, 2029
(6 years from now) | |
|
US8827963
(Pediatric) | ASTRAZENECA AB | Administering device with holding mechanism |
Aug, 2029
(6 years from now) | |
|
US8690837
(Pediatric) | ASTRAZENECA AB | Mixing device for a two-chamber ampoule |
Nov, 2029
(6 years from now) | |
| US8998876 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(6 years from now) | |
| US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(6 years from now) | |
|
US8998876
(Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(7 years from now) | |
|
US8721615
(Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jul 22, 2024 |
| M | Feb 15, 2022 |
| Pediatric Exclusivity (PED) | Jan 22, 2025 |
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; Reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
2. List of Bydureon Bcise drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7223440
(Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Mar, 2022
(11 months ago) | |
| US6824822 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Oct, 2022
(3 months ago) | |
|
US6824822
(Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Apr, 2023
(2 months from now) | |
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 2 months from now) | |
| US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 2 months from now) | |
|
US9238076
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(1 year, 8 months from now) | |
|
US7563871
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(1 year, 8 months from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(2 years from now) | |
|
US7612176
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(2 years from now) | |
|
US8431685
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(2 years from now) | |
|
US8461105
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(2 years from now) | |
|
US7456254
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(2 years from now) | |
|
US6515117
(Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(3 years from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(3 years from now) | |
| US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(3 years from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(3 years from now) | |
|
US9884092
(Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(4 years from now) | |
|
US8329648
(Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(4 years from now) | |
|
US8906851
(Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(4 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
|
US8501698
(Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(4 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
|
US8361972
(Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(5 years from now) | |
| US8895033 | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Oct, 2030
(7 years from now) | |
|
US8895033
(Pediatric) | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Apr, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jul 22, 2024 |
| M | Feb 15, 2022 |
| Pediatric Exclusivity (PED) | Jan 22, 2025 |
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Stimulating insulin release in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; Delaying gastric emptying in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic